The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| GLPG | +14.82% | -73.57% | -23.35% | +302% |
| S&P | +12.65% | +91.73% | +13.89% | +437% |
Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. Its clinical pipeline includes filgotinib, GLP3667, Toledo program, and idiopathic pulmonary fibrosis. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.
A high-profile healthcare industry executive has been tapped as the company's new CEO.
The company's new salt-inducable kinase inhibitor program is getting off to a rocky start.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $83.16M | 26.5% |
| Gross Profit | $70.48M | 7.2% |
| Gross Margin | 84.76% | -15.2% |
| Market Cap | $2.28B | 20.3% |
| Market Cap / Employee | $3.24M | 0.0% |
| Employees | 704 | 0.0% |
| Net Income | -$238.38M | -346.8% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $75.74M | -29.6% |
| Accounts Receivable | $53.26M | 5.1% |
| Inventory | 27 | -63.1% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $6.77M | -16.2% |
| Short Term Debt | $2.04M | -56.7% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -11.37% | 0.0% |
| Return On Invested Capital | -3.72% | -1.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$63.58M | 17.0% |
| Operating Free Cash Flow | -$60.00M | 16.6% |
| Metric | Q4 2024 | YoY Change | |||
|---|---|---|---|---|---|
| Price to Earnings | 22.88 | - | |||
| Price to Book | 0.57 | 0.55 | 0.62 | 0.74 | 23.86% |
| Price to Sales | 6.08 | 5.36 | 6.16 | 7.21 | - |
| Price to Tangible Book Value | 0.62 | 0.60 | 0.68 | 0.80 | 23.47% |
| Return on Equity | -6.3% | -10.1% | -16.4% | - | |
| Total Debt | $12.14M | $11.73M | $9.91M | $8.81M | -31.11% |
No podcast episodes available.
GLPG earnings call for the period ending September 30, 2021.
GLPG earnings call for the period ending June 30, 2021.
GLPG earnings call for the period ending March 31, 2021.
GLPG earnings call for the period ending December 31, 2020.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
